search
Back to results

18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Technosphere Insulin
Technosphere Placebo
Sponsored by
Mannkind Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and females patients from 18 to <80 years of age
  • Clinical diagnosis of type 2 diabetes mellitus
  • Duration of diabetes of >3 years and <20 years
  • Glycemic control at upper end of acceptable level or sub-optimal in control (HbA1c between 7.0% and 12?0%)
  • Confirmation of diagnosis of diabetes such as a history of 2 hour postprandial blood glucose >11.1 mmol/L (200 mg/dL) or following a glucose tolerance test
  • A minimum of 2 months of treatment with a stable dose of one or more of the following anti-hyperglycemic agents: sulphonylureas, alpha glucosidase inhibitors, metformin, meglitinides, thiazolidinediones and/or Lantus basal insulin therapy
  • FBG:>6 mmol/L (108 mg/dL)
  • C-peptide: >0.5 nmol/L
  • BMI <38 kg/m2
  • Baseline DLco, FVC, FEV1 >75% of predicted normal
  • Subjects who, in the opinion of the Investigator, will be able to complete this study
  • Written informed consent

Exclusion Criteria:

  • Severe complications of diabetes including history of: blindness from or grade III or IV diabetic retinopathy, renal failure requiring dialysis or transplantation, amputation of limbs or digits related to diabetic vasculopathy or foot ulcers
  • Treatment with another investigational drug within 3 months prior to study entry and for the duration of the study
  • History of drug or alcohol dependency
  • Significant hepatic disease (as evidenced by ALT or AST >3 times the normal upper reference range or bilirubin >1.5 times the normal upper reference range)
  • Significant renal disease (as evidenced by creatinine >1.5 mg/dL for males or >1.3 mg/dL for females) or proteinuria >1,000 mg/24 hours
  • History of chronic obstructive pulmonary disease, or history of other known chronic pulmonary diseases, such as reactive airway disease, chronic bronchitis, emphysema, or asthma
  • Heart disease graded as class III or class IV according to New York Heart Association criteria
  • Prior treatment with , or participation in a clinical study involving an inhaled insulin product
  • Smokers
  • Current use of preprandial or prandially administered fast-acting or rapid acting insulin or insulin analogs
  • Previous participation in a TI or TP clinical trial
  • Allergy to insulin or to any drugs to be used as part of the clinical trial
  • History of malignancy within 5 years of study entry (other than basal cell carcinoma)
  • Anemia (hemoglobin level less than 11 g/dL for females or 12 g/dL for males at study entry)
  • Diagnosis of Acquired Immunodeficiency Syndrome (AIDS) and Aids Related Complex A major psychiatric disorder that will preclude satisfactory participation in this study
  • Subjects who have had a myocardial infarction or stroke within the preceding 6 months
  • Prior diagnosis of systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine
  • History of severe or multiple allergies
  • Progressive fatal disease
  • Recent loss (within the past 2 months) of >5% of body weight
  • Evidence of "moderate" or greater ketones in urine or history of ketoacidosis
  • Use of medications known to modify glucose metabolism or the ability to recover from hypoglycemia such as oral, parenteral and inhaled steroids, or greater than 25 mg hydrochlorothiazide daily
  • Women who are pregnant or lactating
  • Women of childbearing potential practicing inadequate birth control (adequate birth control is defined as using oral contraceptives, condoms or diaphragms with spermicide, intrauterine devices, or surgical sterilization).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Technosphere Insulin

    Technosphere Inhalation Powder

    Arm Description

    Outcomes

    Primary Outcome Measures

    HbA1c change from baseline (week 6) to end of treatment (week 17)
    Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline.
    Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after TI administration
    Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline)
    Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after Technosphere Placebo administration

    Secondary Outcome Measures

    Fasting blood glucose concentration compared to week 6 (baseline)
    Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations

    Full Information

    First Posted
    August 3, 2007
    Last Updated
    April 27, 2012
    Sponsor
    Mannkind Corporation
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00511732
    Brief Title
    18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes
    Official Title
    A Randomized, Double-blind, Controlled, Stepwise Titration Study to Evaluate Dose Response to Prandial Administration of Inhaled Technosphere/Insulin or Technosphere in Patients With Type 2 Diabetes Mellitus Who Are Sub-optimally Treated
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2012
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2004 (undefined)
    Primary Completion Date
    August 2005 (Actual)
    Study Completion Date
    August 2007 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Mannkind Corporation

    4. Oversight

    5. Study Description

    Brief Summary
    Designed to evaluate dose response of force-titrated prandial administration of TI as compared to placebo (TP) in subjects with Type 2 diabetes who were suboptimally controlled

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    227 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Technosphere Insulin
    Arm Type
    Experimental
    Arm Title
    Technosphere Inhalation Powder
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Technosphere Insulin
    Intervention Description
    Technosphere Insulin Inhalation Powder
    Intervention Type
    Drug
    Intervention Name(s)
    Technosphere Placebo
    Intervention Description
    Technosphere Inhalation Powder
    Primary Outcome Measure Information:
    Title
    HbA1c change from baseline (week 6) to end of treatment (week 17)
    Time Frame
    measured from week 6 (baseline) to week 17
    Title
    Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline.
    Description
    Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after TI administration
    Time Frame
    at weeks 4, 6, 11 and 17
    Title
    Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline)
    Description
    Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after Technosphere Placebo administration
    Time Frame
    at weeks 4, 6, 11 and 17
    Secondary Outcome Measure Information:
    Title
    Fasting blood glucose concentration compared to week 6 (baseline)
    Time Frame
    at weeks 4, 6, 11 and 17
    Title
    Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations
    Time Frame
    18 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male and females patients from 18 to <80 years of age Clinical diagnosis of type 2 diabetes mellitus Duration of diabetes of >3 years and <20 years Glycemic control at upper end of acceptable level or sub-optimal in control (HbA1c between 7.0% and 12?0%) Confirmation of diagnosis of diabetes such as a history of 2 hour postprandial blood glucose >11.1 mmol/L (200 mg/dL) or following a glucose tolerance test A minimum of 2 months of treatment with a stable dose of one or more of the following anti-hyperglycemic agents: sulphonylureas, alpha glucosidase inhibitors, metformin, meglitinides, thiazolidinediones and/or Lantus basal insulin therapy FBG:>6 mmol/L (108 mg/dL) C-peptide: >0.5 nmol/L BMI <38 kg/m2 Baseline DLco, FVC, FEV1 >75% of predicted normal Subjects who, in the opinion of the Investigator, will be able to complete this study Written informed consent Exclusion Criteria: Severe complications of diabetes including history of: blindness from or grade III or IV diabetic retinopathy, renal failure requiring dialysis or transplantation, amputation of limbs or digits related to diabetic vasculopathy or foot ulcers Treatment with another investigational drug within 3 months prior to study entry and for the duration of the study History of drug or alcohol dependency Significant hepatic disease (as evidenced by ALT or AST >3 times the normal upper reference range or bilirubin >1.5 times the normal upper reference range) Significant renal disease (as evidenced by creatinine >1.5 mg/dL for males or >1.3 mg/dL for females) or proteinuria >1,000 mg/24 hours History of chronic obstructive pulmonary disease, or history of other known chronic pulmonary diseases, such as reactive airway disease, chronic bronchitis, emphysema, or asthma Heart disease graded as class III or class IV according to New York Heart Association criteria Prior treatment with , or participation in a clinical study involving an inhaled insulin product Smokers Current use of preprandial or prandially administered fast-acting or rapid acting insulin or insulin analogs Previous participation in a TI or TP clinical trial Allergy to insulin or to any drugs to be used as part of the clinical trial History of malignancy within 5 years of study entry (other than basal cell carcinoma) Anemia (hemoglobin level less than 11 g/dL for females or 12 g/dL for males at study entry) Diagnosis of Acquired Immunodeficiency Syndrome (AIDS) and Aids Related Complex A major psychiatric disorder that will preclude satisfactory participation in this study Subjects who have had a myocardial infarction or stroke within the preceding 6 months Prior diagnosis of systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine History of severe or multiple allergies Progressive fatal disease Recent loss (within the past 2 months) of >5% of body weight Evidence of "moderate" or greater ketones in urine or history of ketoacidosis Use of medications known to modify glucose metabolism or the ability to recover from hypoglycemia such as oral, parenteral and inhaled steroids, or greater than 25 mg hydrochlorothiazide daily Women who are pregnant or lactating Women of childbearing potential practicing inadequate birth control (adequate birth control is defined as using oral contraceptives, condoms or diaphragms with spermicide, intrauterine devices, or surgical sterilization).
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Anders Boss
    Organizational Affiliation
    Mannkind Corporation
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes

    We'll reach out to this number within 24 hrs